Overview

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Status:
Recruiting

Trial end date:
2024-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate safety and anti-tumor activity of relatlimab combination therapy in solid cancers that are advanced or have spread

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Ipilimumab
Linrodostat
Nivolumab